A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings

被引：0
|
作者：
Jonker, D. J.
Rosen, L. S.
Sawyer, M.
Wilding, G.
Noberasco, C.
Jayson, G.
Rustin, G.
McArthur, G.
Velasquez, L.
Galbraith, S.
机构：
[1] Ottawa Reg Canc Ctr, Ottawa, ON, Canada
[2] Premiere Oncol, Santa Monica, CA USA
[3] Cross Canc Inst, Edmonton, AB, Canada
[4] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[5] Ist Europeo Oncol, Milan, Italy
[6] Christie Hosp, Manchester, Lancs, England
[7] Mt Vernon Canc Ctr, Northwood, Middx, England
[8] Peter MacCallum Canc Ctr, East Melbourne, Australia
[9] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
    Okamoto, Isamu
    Kaneda, Hiroyasu
    Satoh, Taroh
    Okamoto, Wataru
    Miyazaki, Masaki
    Morinaga, Ryotaro
    Ueda, Shinya
    Terashima, Masaaki
    Tsuya, Asuka
    Sarashina, Akiko
    Konishi, Koichi
    Arao, Tokuzo
    Nishio, Kazuto
    Kaiser, Rolf
    Nakagawa, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2825 - 2833
  • [22] Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    O'Donnell, Anne
    Faivre, Sandrine
    Burris, Howard A., III
    Rea, Daniel
    Papadimitrakopoulou, Vassiliki
    Shand, Nicholas
    Lane, Heidi A.
    Hazell, Katharine
    Zoellner, Ulrike
    Kovarik, John M.
    Brock, Cathryn
    Jones, Suzanne
    Raymond, Eric
    Judson, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1588 - 1595
  • [23] Safety, pharmacokinetic (PK), and pharmacodynamic profiles of the WEE1 inhibitor IMP7068 in patients (pts) with advanced solid tumors
    Lin, C-C.
    Grewal, J.
    Sommerhalder, D.
    Bai, L-Y.
    Li, G.
    Schneider, R.
    Shen, L.
    Yeh, Y-M.
    Yin, R.
    Hsu, H-C.
    Baranda, J. C.
    Hsieh, C-Y.
    Cai, S. X.
    Tian, Y. E.
    Ma, N.
    Xia, H.
    Zhang, C.
    Li, B.
    Zhang, M.
    Yu, Z.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S760 - S761
  • [24] A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GT12040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors
    Takimoto, Chris H.
    Chu, Quincy S-C
    Yen, Yun
    O'Rourke, Patricia
    Cooper, Joshua
    Pardo, Sam
    Tolcher, Anthony W.
    Patnaik, Amita
    Papadopoulos, Kyriakos
    Beeram, Muralidhar
    Ricart, Alejandro D.
    Lin, Chia-Chi
    Mita, Alain C.
    Calvo, Emiliano
    Espinoza-Delgado, Igor
    Zwiebel, Jamie
    Sarantopoulos, John
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3579S - 3579S
  • [25] A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors.
    Ricart, A. D.
    Cooney, M.
    Sarantopoulos, J.
    Brell, J.
    Locke, K. W.
    Gammans, R. E.
    Medina, G.
    Zambito, A.
    Tolcher, A. W.
    Remick, S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 144S - 144S
  • [26] A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study of the sachet formulation of the oral dual PI3K-mTOR inhibitor BEZ235 given twice daily (BID) in patients (pts) with advanced solid tumors.
    Bendell, Johanna C.
    Kurkjian, Carla
    Infante, Jeffrey R.
    Bauer, Todd
    Burris, Howard A.
    Spigel, David R.
    Yardley, Denise A.
    Greco, F. Anthony
    Shih, Kent C.
    Thompson, Dana S.
    Jones, Suzanne F.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [27] Pharmacokinetic(PK) and pharmacodynamic(PD) results of a phase I study of PD-0325901, a second generation oral MEK inhibitor, in patients with advanced cancer
    Tan, Weiwei
    DePrimo, Samuel
    Krishnamurthi, Smitha S.
    Rinehart, John J.
    Nabell, Lisle M.
    Nickens, Dana
    Bentivegna, Steven
    Wilner, Keith D.
    Ricart, Alejandro D.
    LoRusso, Patricia M.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3468S - 3468S
  • [28] First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Shen, Lin
    Gong, Jifang
    Huang, Cheng
    Ye, Chen Yang
    Yang, Li
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] A phase I pharmacodynamic and pharmacokinetic study of a Ras inhibitor, PRLX 93936, in patients with advanced solid tumors
    Ramanathan, R. K.
    Rosen, P. J.
    Wagner, A. J.
    Sahasrabudhe, S.
    Weiss, G. J.
    Lee, P.
    Fuerst, M.
    Robbins, P.
    Litka, P.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] A pharmacokinetic (PK) and pharmacodynamic (PD) biomarker-driven phase I study of intermittent, low dose intensity schedules of the dual MEK/RAF inhibitor, RO5126766 (RO) in patients (pts) with advanced solid tumors
    Luken, Maria Jose de Miguel
    Roda, Desamparados
    Lopez, Raquel Perez
    Jimenez, Begona
    Hassam, Hasina
    Sathiyayogan, Nitharsan
    Parmar, Mona
    Turner, Alison Joanne
    Hall, Emma
    Tunariu, Nina
    Molife, L. Rhoda
    Yap, Timothy Anthony
    De Bono, Johann Sebastian
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345